Actively Recruiting

Phase 4
Age: 6Years - 8Years
All Genders
NCT05517655

BEGIN Novel ImagiNG Biomarkers

Led by Children's Hospital Medical Center, Cincinnati · Updated on 2024-11-21

44

Participants Needed

3

Research Sites

339 weeks

Total Duration

On this page

Sponsors

C

Children's Hospital Medical Center, Cincinnati

Lead Sponsor

U

University of Kansas

Collaborating Sponsor

AI-Summary

What this Trial Is About

To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).

CONDITIONS

Official Title

BEGIN Novel ImagiNG Biomarkers

Who Can Participate

Age: 6Years - 8Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent and assent when appropriate obtained
  • Willingness to follow the study visit schedule and protocol requirements
  • Children aged 6 to 8 years at baseline MRI visit (enrollment allowed up to 60 days before 6th birthday)
  • Confirmed cystic fibrosis diagnosis by clinical features and either sweat chloride ≥60 mEq/liter or two CFTR gene mutations
  • Physician plans to prescribe triple-combination therapy
  • Clinically stable with no respiratory infection at enrollment
  • No changes in chronic maintenance therapies in the 28 days before enrollment
  • Ability to cooperate with MRI procedures
Not Eligible

You will not qualify if you...

  • Current use of ivacaftor therapies with at least one gating mutation (e.g., G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D)
  • Acute respiratory symptoms such as wheezing at MRI time
  • Acute respiratory infection within 28 days before enrollment
  • Chronic lung disease not related to cystic fibrosis
  • Chronic liver disease not related to cystic fibrosis
  • Acute pancreatitis by clinical criteria
  • Chronic pancreatic disease not related to cystic fibrosis
  • Any physical condition risking safety or study data quality per investigator
  • Any other condition impairing consent, safety, data interpretation, or study objectives as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

Active, Not Recruiting

2

Carrie Stevens

Cincinnati, Ohio, United States, 45229

Active, Not Recruiting

3

University of Virginia

Charlottesville, Virginia, United States, 22903

Actively Recruiting

Loading map...

Research Team

C

Carrie Stevens, BS

CONTACT

P

Penny New, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

CROSSOVER

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here